PLoS Genetics (Sep 2014)

Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias.

  • Gary W Beecham,
  • Kara Hamilton,
  • Adam C Naj,
  • Eden R Martin,
  • Matt Huentelman,
  • Amanda J Myers,
  • Jason J Corneveaux,
  • John Hardy,
  • Jean-Paul Vonsattel,
  • Steven G Younkin,
  • David A Bennett,
  • Philip L De Jager,
  • Eric B Larson,
  • Paul K Crane,
  • M Ilyas Kamboh,
  • Julia K Kofler,
  • Deborah C Mash,
  • Linda Duque,
  • John R Gilbert,
  • Harry Gwirtsman,
  • Joseph D Buxbaum,
  • Patricia Kramer,
  • Dennis W Dickson,
  • Lindsay A Farrer,
  • Matthew P Frosch,
  • Bernardino Ghetti,
  • Jonathan L Haines,
  • Bradley T Hyman,
  • Walter A Kukull,
  • Richard P Mayeux,
  • Margaret A Pericak-Vance,
  • Julie A Schneider,
  • John Q Trojanowski,
  • Eric M Reiman,
  • Alzheimer's Disease Genetics Consortium (ADGC),
  • Gerard D Schellenberg,
  • Thomas J Montine

DOI
https://doi.org/10.1371/journal.pgen.1004606
Journal volume & issue
Vol. 10, no. 9
p. e1004606

Abstract

Read online

Alzheimer's disease (AD) and related dementias are a major public health challenge and present a therapeutic imperative for which we need additional insight into molecular pathogenesis. We performed a genome-wide association study and analysis of known genetic risk loci for AD dementia using neuropathologic data from 4,914 brain autopsies. Neuropathologic data were used to define clinico-pathologic AD dementia or controls, assess core neuropathologic features of AD (neuritic plaques, NPs; neurofibrillary tangles, NFTs), and evaluate commonly co-morbid neuropathologic changes: cerebral amyloid angiopathy (CAA), Lewy body disease (LBD), hippocampal sclerosis of the elderly (HS), and vascular brain injury (VBI). Genome-wide significance was observed for clinico-pathologic AD dementia, NPs, NFTs, CAA, and LBD with a number of variants in and around the apolipoprotein E gene (APOE). GalNAc transferase 7 (GALNT7), ATP-Binding Cassette, Sub-Family G (WHITE), Member 1 (ABCG1), and an intergenic region on chromosome 9 were associated with NP score; and Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Beta Member 2 (KCNMB2) was strongly associated with HS. Twelve of the 21 non-APOE genetic risk loci for clinically-defined AD dementia were confirmed in our clinico-pathologic sample: CR1, BIN1, CLU, MS4A6A, PICALM, ABCA7, CD33, PTK2B, SORL1, MEF2C, ZCWPW1, and CASS4 with 9 of these 12 loci showing larger odds ratio in the clinico-pathologic sample. Correlation of effect sizes for risk of AD dementia with effect size for NFTs or NPs showed positive correlation, while those for risk of VBI showed a moderate negative correlation. The other co-morbid neuropathologic features showed only nominal association with the known AD loci. Our results discovered new genetic associations with specific neuropathologic features and aligned known genetic risk for AD dementia with specific neuropathologic changes in the largest brain autopsy study of AD and related dementias.